These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22720798)

  • 1. Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review.
    Yanuck D; Mihos CG; Santana O
    Int J Neurosci; 2012 Nov; 122(11):619-29. PubMed ID: 22720798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.
    Mihos CG; Salas MJ; Santana O
    Cardiol Rev; 2010; 18(6):298-304. PubMed ID: 20926939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in gastrointestinal tract disorders: a comprehensive review.
    Cortes-Bergoderi M; Pineda AM; Santana O
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):199-204. PubMed ID: 23799219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review.
    Zeichner S; Mihos CG; Santana O
    J Cancer Res Ther; 2012; 8(2):176-83. PubMed ID: 22842358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review.
    Mihos CG; Artola RT; Santana O
    Rheumatol Int; 2012 Feb; 32(2):287-94. PubMed ID: 21805349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins.
    Schmeer C; Kretz A; Isenmann S
    Restor Neurol Neurosci; 2006; 24(2):79-95. PubMed ID: 16720944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations of statins in heart failure: inflammatory biomarkers and hormones.
    Khan BV; Rajagopalan S
    Heart Fail Clin; 2008 Apr; 4(2):171-6. PubMed ID: 18433697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
    Krishna RK; Issa O; Saha D; Macedo FY; Correal B; Santana O
    Pulm Pharmacol Ther; 2015 Feb; 30():134-40. PubMed ID: 25173913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of statins, beyond lipid-lowering properties.
    Mihos CG; Pineda AM; Santana O
    Pharmacol Res; 2014 Oct; 88():12-9. PubMed ID: 24631782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins--a cure-all for the brain?
    Menge T; Hartung HP; Stüve O
    Nat Rev Neurosci; 2005 Apr; 6(4):325-31. PubMed ID: 15803163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential therapeutic role of statins in central nervous system autoimmune disorders.
    Stüve O; Youssef S; Dunn S; Slavin AJ; Steinman L; Zamvil SS
    Cell Mol Life Sci; 2003 Nov; 60(11):2483-91. PubMed ID: 14625690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of statins beyond lipid lowering: potential for clinical benefits.
    Almuti K; Rimawi R; Spevack D; Ostfeld RJ
    Int J Cardiol; 2006 Apr; 109(1):7-15. PubMed ID: 16054715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and prevention of atrial fibrillation in patients with heart failure.
    Liu T; Li G; Korantzopoulos P; Goudevenos JA
    Int J Cardiol; 2009 Jul; 135(3):e83-4. PubMed ID: 18625529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke.
    Moonis M; Fisher M
    Expert Rev Neurother; 2004 Mar; 4(2):241-7. PubMed ID: 15853565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Statins in stroke prevention].
    Gedikli O; Baykan M
    Anadolu Kardiyol Derg; 2008 Jun; 8(3):217-22. PubMed ID: 18524729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The pleiotropic effects of statins].
    Wolfovitz E
    Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutic role of statins in neurological disorders.
    Bifulco M; Malfitano AM; Marasco G
    Expert Rev Neurother; 2008 May; 8(5):827-37. PubMed ID: 18457539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Statins in the Treatment and Prevention of Atrial Fibrillation.
    Groves D; Mihos CG; Larrauri-Reyes M; Santana O
    Cardiol Rev; 2016; 24(5):224-9. PubMed ID: 26401903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.